Nomura Asset Management
RXRX icon

Nomura Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Nomura Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-56,310
Closed -$381K – 1572
2024
Q4 		$381K Hold
56,310
– – ﹤0.01% 854
2024
Q3 		$371K Hold
56,310
– – ﹤0.01% 846
2024
Q2 		$422K Hold
56,310
– – ﹤0.01% 849
2024
Q1 		$561K Buy
56,310
+9,941
+21% +$111K ﹤0.01% 829
2023
Q4 		$457K Buy
+46,369
New +$331K ﹤0.01% 853

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Nomura Asset Management's RXRX Position: Q1 2025 in Review

Nomura Asset Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2025, closing a stake of 56,310 shares — an estimated $381K sold.

Nomura Asset Management first reported a position in RXRX in Q4 2023 and held it in 5 quarters. The position peaked at $561K in Q1 2024. 336 funds tracked by Wall St. Rank hold RXRX as of Q1 2025.

  • Nomura Asset Management reported no remaining Recursion Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Nomura Asset Management sold 56,310 Recursion Pharmaceuticals shares in Q1 2025, an estimated $381K.
  • Nomura Asset Management first reported a position in Recursion Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Nomura Asset Management's Recursion Pharmaceuticals position peaked at $561K in Q1 2024.
  • 336 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2025.

Based on Nomura Asset Management's 13F filing for Q1 2025, filed 12 May 2025.